Biomedical Engineering Reference
In-Depth Information
Cole C, Foster AJ, Freeman S, Jaffar M, Murray PE, Strafford IJ (1999) The role of thymidine
phosphorylase/PD-ECGF in cancer chemotherapy: a chemical perspective. Anticancer Drug
Des 14 (5):383-392
Connors TA (1986) Prodrugs in cancer chemotherapy. Xenobiotica 16 (10-11):975-988.
doi:10.3109/00498258609038977
Corr SC, Gahan CC, Hill C (2008) M-cells: origin, morphology and role in mucosal immunity and
microbial pathogenesis. FEMS Immunol Med Microbiol 52 (1):2-12. doi:FIM359 [pii]
10.1111/j.1574-695X.2007.00359.x
Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ
(1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropy-
ldibenzosuberane modulator, LY335979. Cancer Res 56 (18):4171-4179
Demeule M, Laplante A, Sepehr-Arae A, Beaulieu E, Averill-Bates D, Wenger RM, Beliveau R
(1999) Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. Biochem
Cell Biol 77 (1):47-58
des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V (2006) Nanoparticles as potential oral
delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116
(1):1-27. doi:S0168-3659(06)00402-0 [pii] 10.1016/j.jconrel.2006.08.013
Dong Y, Feng SS (2005) Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral
delivery of anticancer drugs. Biomaterials 26 (30):6068-6076. doi:S0142-9612(05)00256-5
[pii] 10.1016/j.biomaterials.2005.03.021
Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AE (1998) The
multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome
P450 3A. Implications for drug-drug interactions and pharmacological activity of the main
metabolite. Drug Metab Dispos 26 (8):802-811
Foger F, Schmitz T, Bernkop-Schnurch A (2006) In vivo evaluation of an oral delivery system for
P-gp substrates based on thiolated chitosan. Biomaterials 27 (23):4250-4255. doi:S0142-
9612(06)00268-7 [pii] 10.1016/j.biomaterials.2006.03.033
Ganta S, Devalapally H, Amiji M (2010) Curcumin enhances oral bioavailability and anti-tumor
therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm
Sci 99 (11):4630-4641. doi:10.1002/jps.22157
Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, Kuo MS, Hageman MJ (2003)
Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved
oral bioavailability. J Pharm Sci 92 (12):2386-2398. doi:10.1002/jps.10511
Gao P, Akrami A, Alvarez F, Hu J, Li L, Ma C, Surapaneni S (2009) Characterization and optimi-
zation of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for
improved oral absorption. J Pharm Sci 98 (2):516-528. doi:10.1002/jps.21451
Gaucher G, Satturwar P, Jones MC, Furtos A, Leroux JC (2010) Polymeric micelles for oral drug
delivery. Eur J Pharm Biopharm 76 (2):147-158. doi:S0939-6411(10)00156-6 [pii] 10.1016/j.
ejpb.2010.06.007
Ge W, Li Y, Li ZS, Zhang SH, Sun YJ, Hu PZ, Wang XM, Huang Y, Si SY, Zhang XM, Sui YF
(2009) The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-
HSP70/SEA complex protein vaccine following peroral administration route. Cancer Immunol
Immunother 58 (2):201-208. doi:10.1007/s00262-008-0539-9.
Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev
Pharmacol Toxicol 39:1-17. doi:10.1146/annurev.pharmtox.39.1.1
Guerquin-Kern JL, Volk A, Chenu E, Lougerstay-Madec R, Monneret C, Florent JC, Carrez D,
Croisy A (2000) Direct in vivo observation of 5-fluorouracil release from a prodrug in human
tumors heterotransplanted in nude mice: a magnetic resonance study. NMR Biomed 13
(5):306-310. doi:10.1002/1099-1492(200008)13:5<306::AID-NBM639>3.0.CO;2-P [pii]
Guo X, Lerner-Tung M, Chen HX, Chang CN, Zhu JL, Chang CP, Pizzorno G, Lin TS, Cheng YC
(1995) 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil.
Biochem Pharmacol 49 (8):1111-1116. doi:0006-2952(95)98508-7 [pii]
Higgins JP, Bernstein MB, Hodge JW (2009) Enhancing immune responses to tumor-associated
antigens. Cancer Biol Ther 8 (15):1440-1449. doi:9133 [pii]
Search WWH ::
Custom Search